Filing Flows

Filing Flows › Companies › Innoviva › Cash flow

Innoviva cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$41.7M in Q3 2026 · $183M over twelve months

Operating cash flow$41.7M
Capital spending−$24K
Free cash flow+$41.7M

Analysis

In Q3 2026, Innoviva generated $41.7M of operating cash flow and spent $24K on capital projects, leaving free cash flow of $41.7M. That is $6.9M less than in Q3 2025 ($48.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was $183M; the largest uses were buybacks ($81.9M), capital spending ($955K), taxes on employees’ shares ($339K); besides operations, cash came from shares issued ($3.7M), other investing ($684K); the cash balance rose by $105M.

Operating cash flow was $41.7M against net income of −$73.9M. The largest differences: income taxes payable −$40.5M, prepaid and other assets +$36.2M, deferred taxes −$29.8M.

Free cash flow

Innoviva: free cash flow by quarterInnoviva: free cash flow by quarter$59.2MQ4 2024$48.6MQ1 2025$44.1MQ2 2025$48.6MQ3 2025$54.5MQ4 2025$34.8MQ1 2026$51.5MQ2 2026$41.7MQ3 2026
Operating cash flow less capital spending.
Innoviva: operating cash flow against capital spendingInnoviva: operating cash flow against capital spendingOperating cash flowCapital spending$59.2M$0Q4 2024$48.6M$0Q1 2025$44.1M$0Q2 2025$49.7M$1.1MQ3 2025$54.5M$10KQ4 2025$35.3M$492KQ1 2026$52.0M$429KQ2 2026$41.7M$24KQ3 2026
Latest (Q3 2026): Operating cash flow $41.7M, Capital spending $24K.

Capital allocation, year by year

Innoviva: where the cash came from (up) and went (down), by fiscal yearInnoviva: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow $364MFY2021: Shares issued $1.2MFY2021: Buybacks −$394M$365MFY2021FY2022: Operating cash flow $202MFY2022: Net borrowing $87.4MFY2022: Shares issued $370KFY2022: Capital spending −$67KFY2022: Buybacks −$8.5M$290MFY2022FY2023: Operating cash flow $141MFY2023: Net borrowing −$96.2MFY2023: Shares issued $170KFY2023: Capital spending −$411KFY2023: Buybacks −$75.7M$141MFY2023FY2024: Operating cash flow $189MFY2024: Shares issued $1.5MFY2024: Asset sales $101KFY2024: Capital spending −$270KFY2024: Buybacks −$14.8M$190MFY2024FY2025: Operating cash flow $197MFY2025: Shares issued $2.6MFY2025: Asset sales $12KFY2025: Capital spending −$1.1MFY2025: Buybacks −$4.5M$199MFY2025
Over these 5 years operating cash flow totalled $1.1B; the largest uses were buybacks ($498M) and net borrowing ($96.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$581M
Debt$259M
Net cash$323M

Innoviva funds itself: free cash flow was $183M over the last twelve months, and $581M of cash and investments stands against $259M of debt.

Where the cash came from and went

Innoviva: sources (+) and uses (−) of cash, Q3 2026Innoviva: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$41.7MBuybacks−$26.1MCash drawn (+) / kept (−)−$11.0MOther investing−$5.4MShares issued$869KTaxes on employees’ shares−$60KAsset & business sales$25KCapital spending−$24K
Innoviva: sources (+) and uses (−) of cash, TTM to Q3 2026Innoviva: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$183MCash drawn (+) / kept (−)−$105MBuybacks−$81.9MShares issued$3.7MCapital spending−$955KOther investing$684KTaxes on employees’ shares−$339KAsset & business sales$222K

From profit to cash

Innoviva: net income to operating cash flow, Q3 2026Innoviva: net income to operating cash flow, Q3 2026Net income−$73.9MStock-based pay$3.7MDeferred taxes−$29.8MOther non-cash$666KReceivables$6.8MInventory−$4.6MPayables$2.5MAccrued liabilities$735KDeferred revenue−$1.0MPrepaid and other assets$36.2MIncome taxes payable−$40.5MOperating cash flow$41.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingBuybacksShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$41.7M−$24K−$26.1M$869K−$11.0M$41.7M
Q2 2026$52.0M−$429K−$31.1M$1.8M$32.7M$51.5M
Q1 2026$35.3M−$492K−$20.2M$259K−$52.1M$34.8M
Q4 2025$54.5M−$10K−$4.5M$838K−$74.4M$54.5M
Q3 2025$49.7M−$1.1M—$194K−$79.0M$48.6M
Q2 2025$44.1M——$1.3M−$78.4M$44.1M
Q1 2025$48.6M——$250K−$14.1M$48.6M
Q4 2024$59.2M——$592K−$44.3M$59.2M

Innoviva: income statement and cash flow

Innoviva, Q3 2026: revenue $106M (-2% year over year), operating margin 39.7%. The chart follows the revenue to costs, profit and cash.

Innoviva: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.